Highlights
- •Internal dosimetry for Alfatide II using the ICRP 110 phantoms for the first time.
- •The effective dose of Alfatide II using the ICRP 103 method is 1.33E-02 mSv/MBq.
- •The estimated effective dose in this study is lower than previously published data.
- •The lungs have the highest contribution to the effective dose.
- •The effective dose coefficient of Alfatide II is lower than FDG.
Abstract
Purpose
18F-alfatide II is an arginine-glycine-aspartate (RGD) peptide-based PET tracer with
promising imaging properties and pharmacokinetics. This study aims to calculate the
absorbed and effective doses of 18F-alfatide II using the ICRP 110 adult reference phantoms and the ICRP 103 tissue
weighting factors.
Methods
The MIRD method was used in this study to calculate the absorbed dose of organs and
tissues. The biokinetic data were taken from a previous study. These data are based
on the whole-body PET imaging of mice.
Results
The results show that the effective dose per unit activity administered of 18F-alfatide II is 1.33E-02 mSv/MBq. The urinary bladder wall receives the highest absorbed
dose due to the administration of this radiopharmaceutical. Also, the effective dose
of 18F-alfatide II is lower than that of 18F-FDG and some other RGD peptide-based tracers.
Conclusions
Dose calculation using ICRP 110 voxelized adult reference phantoms and ICRP 103 tissue
weighting factors leads to more realistic and accurate results for 18F-alfatide II
compared to the stylized phantoms. The calculated effective dose of 18F-alfatide II in the present study is lower than that of previously published data.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Physica Medica: European Journal of Medical PhysicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.J Nucl Med. 2014; 55: 154-160
- (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases.Eur J Nucl Med Mol Imaging. 2015; 42: 2021-2028
- 18F-Alfatide II for the evaluation of axillary lymph nodes in breast cancer patients: comparison with 18F-FDG.Eur J Nucl Med Mol Imaging. 2022;
- RGD PET: From Lesion Detection to Therapy Response Monitoring.Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016; 57: 501-502
- Comparing the Differential Diagnostic Values of (18)F-Alfatide II PET/CT between Tuberculosis and Lung Cancer Patients.Contrast Media Mol Imaging. 2018; 2018: 8194678
- Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors.Theranostics. 2014; 4: 546-555
- Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.Theranostics. 2015; 5: 1115-1121
- (18)F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study.J Nucl Med. 2018; 59: 1809-1816
- (18)F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer.Translational lung cancer research. 2020; 9: 1324-1332
- Prognosis Evaluation Using (18)F-Alfatide II PET in a Rat Model of Spinal Cord Injury Treated With Estrogen.Mol Imaging. 2020; 19: 1536
- A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer.Sci Rep. 2017; 7
- Radiation dosimetry estimates of 18F-alfatide II based on whole-body PET imaging of mice.Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine. 2015; 105: 1-5
- 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.Nucl Med Biol. 2004; 31: 179-189
- MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides.Mol Imaging Biol. 2004; 6: 350-359
- (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.Eur J Nucl Med Mol Imaging. 2008; 35: 1100-1108
- New Methods for Labeling RGD Peptides with Bromine-76.Theranostics. 2011; 1: 341-353
- MicroPET imaging of integrin αvβ3 expressing tumors using 89Zr-RGD peptides.Mol Imaging Biol. 2011; 13: 1224-1233
- Comparison of three dimeric 18F-AlF-NOTA-RGD tracers.Mol Imaging Biol. 2014; 16: 274-283
- [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck.Clin Cancer Res. 2007; 13: 6610-6616
- Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.J Nucl Med. 2008; 49: 879-886
- 18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology.J Nucl Med. 2015; 56: 361-364
- Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans.J Nucl Med. 2012; 53: 787-795
- Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels.Radiology. 2011; 260: 182-191
- PET monitoring angiogenesis of infarcted myocardium after treatment with vascular endothelial growth factor and bone marrow mesenchymal stem cells.Amino Acids. 2016; 48: 811-820
- First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination.J Nucl Med. 2013; 54: 691-698
- PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2.Eur J Nucl Med Mol Imaging. 2012; 39: 683-692
- 18Falfatide positron emission tomography may predict antiangiogenic responses.Oncol Rep. 2018; 40: 2896-2905
- PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin α(v)β(3) Receptors.Molecules. 2021; 26
- Radiation Dose to Patients from Radiopharmaceuticals.Annals of the ICRP, 1988: 18 (ICRP Publication 53.)
- Radiation Dose to Patients from Radiopharmaceuticals, ICRP Publication 80 (Addendum 2 to ICRP Publication 53).Ann ICRP. 1998; : 28
- Radiation Dose to Patients from Radiopharmaceuticals, ICRP publication 106 (Addendum 3 to ICRP Publication 53).Ann ICRP. 2008; : 38
Cristy, M and Eckerman, KF, Specific absorbed fractions of energy at various ages from internal photon sources. ORNL/TM 8381/V 1-7. 1987, Oak Ridge, TN: Oak Ridge National Laboratory.
ICRP, 1990 Recommendations of the International Commission on Radiological Protection. Ann ICRP, 1991. 21(1-3): p. 1-201.
- Recommendations of the ICRP.Ann. ICRP, 1977: 1 (ICRP Publication 26.)
- Evaluation of absorbed and effective doses to patients from radiopharmaceuticals using the ICRP 110 reference computational phantoms and ICRP 103 formulation.Radiat Prot Dosimetry. 2013; 156: 141-159
- Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors.EJNMMI Phys. 2014; 1: 9
- Adult Reference Computational Phantoms.Annals of the ICRP, 2009: 39 (ICRP Publication 110.)
- Effective dose from radiation exposure in medicine: Past, present, and future.Phys Med. 2020; 79: 87-92
- Appropriate Use of Effective Dose in Radiation Protection and Risk Assessment.Health Phys. 2017; 113: 102-109
- The 2007 Recommendations of the International Commission on Radiological Protection. 2007; 37 (ICRP publication 103.): 1-332
Bolch, WE, Eckerman, KF, Sgouros, G, and Thomas, SR, A generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature, MIRD pamphlet No. 21. J Nucl Med, 2009. 50(3): p. 477-84.
ICRP, Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances. ICRP Publication 128. Annals of the ICRP, 2015. 44.
GATE users guide V8.0, downloaded from: http://www.opengatecollaboration.org/, January 2022.
RADAR - the RAdiation Dose Assessment Resource, The decya data, downloaded from https://www.doseinfo-radar.com/RADARDecay.html, November 2020.
- Physics in Nuclear Medicine.Fourth ed. W.B. Saunders, Philadelphia2012
Leggett, RW, Eckerman, KF, and Meck, RA, Reliability of Current Biokinetic and Dosimetric Models for Radionuclides: A Pilot Study. 2008, Oak Ridge National Lab (ORNL) Oak Ridge, TN (United States).
ICRP, Doses to Members of the Public from Intake of Radionuclides - Part 2 Ingestion Dose Coefficients. ICRP Publication 67. Annals of the ICRP, 1993. 23.
- PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression.J Nucl Med. 2006; 47: 763-769
- The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers.J Nucl Med. 2008; 49: 1664-1667
- (18)F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer.Eur J Nucl Med Mol Imaging. 2016; 43: 2336-2342
- Radiological Protection in Biomedical Research.annals of the ICRP, 1992: 22 (ICRP Publication 62.)
Article info
Publication history
Published online: February 27, 2023
Accepted:
February 18,
2023
Received in revised form:
February 2,
2023
Received:
August 18,
2022
Identification
Copyright
© 2023 Associazione Italiana di Fisica Medica e Sanitaria. Published by Elsevier Ltd. All rights reserved.
